Apnimed, a late-stage drug developer focused on sleep apnea, leapt 38% on Friday after raising $192 million in an upsized US initial public offering. https://t.co/p0bC16q7bn ...

It's a huge day for healthcare numbers from earnings to trial data. So, we're seeing Novo in the red today after the drug maker set a heart drug failed to reduce major cardiovascular events compared to placebo in a late stage trial. The drug lowered markers of inflammation, but it did not translate to a lower risk of cardiovascular death, heart attack, or stroke.So, count analysts are calling this trial failure a major missed opportunity for Novo. You know, analysts have said that this drug represents a way ...